Immunogenicity and safety of different formulations of an adjuvanted glycoprotein D genital herpes vaccine in healthy adults

References

• Looker KJ, Garnett GP, Schmid GP. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. [A.] Bull World Health Organ 2008; 86:805 - 12; http://dx.doi.org/10.2471/BLT.07.046128; PMID: 18949218
   PubMed Web of Science ®Google Scholar
• Bernstein DI. Effects of prior HSV-1 infection on genital HSV-2 infection. Prog Med Virol 1991; 38:109 - 27; PMID: 1647042
   PubMedGoogle Scholar
• Nahmias AJ, Lee FK, Beckman-Nahmias S. Sero-epidemiological and -sociological patterns of herpes simplex virus infection in the world. Scand J Infect Dis Suppl 1990; 69:19 - 36; PMID: 2175939
   PubMedGoogle Scholar
• Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis 2002; 186:Suppl 1 S3 - 28; http://dx.doi.org/10.1086/343739; PMID: 12353183
   PubMed Web of Science ®Google Scholar
• Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006; 296:964 - 73; http://dx.doi.org/10.1001/jama.296.8.964; PMID: 16926356
   PubMed Web of Science ®Google Scholar
• Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992; 116:197 - 202; PMID: 1309413
   PubMed Web of Science ®Google Scholar
• Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T, et al, Valacyclovir HSV Transmission Study Group. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004; 350:11 - 20; http://dx.doi.org/10.1056/NEJMoa035144; PMID: 14702423
   PubMed Web of Science ®Google Scholar
• Marchant J, Roe A. Genital herpes: recognizing and addressing patient's needs. Herpes 1997; 4:36 - 41
   Google Scholar
• Bernstein DI, Aoki FY, Tyring SK, Stanberry LR, St-Pierre C, Shafran SD, et al, GlaxoSmithKline Herpes Vaccine Study Group. Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. Clin Infect Dis 2005; 40:1271 - 81; http://dx.doi.org/10.1086/429240; PMID: 15825029
   PubMed Web of Science ®Google Scholar
• Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S, et al, GlaxoSmithKline Herpes Vaccine Efficacy Study Group. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002; 347:1652 - 61; http://dx.doi.org/10.1056/NEJMoa011915; PMID: 12444179
   PubMed Web of Science ®Google Scholar
• Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, Stapleton JT, et al, Herpevac Trial for Women. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 2012; 366:34 - 43; http://dx.doi.org/10.1056/NEJMoa1103151; PMID: 22216840
   PubMed Web of Science ®Google Scholar
• Mikloska Z, Cunningham AL. Herpes simplex virus type 1 glycoproteins gB, gC and gD are major targets for CD4 T-lymphocyte cytotoxicity in HLA-DR expressing human epidermal keratinocytes. J Gen Virol 1998; 79:353 - 61; PMID: 9472620
   PubMed Web of Science ®Google Scholar
• Schmid DS, Thieme ML, Gary HE Jr., Reeves WC. Characterization of T cell responses to herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2) using a TNF-beta ELISpot cytokine assay. Arch Virol 1997; 142:1659 - 71; http://dx.doi.org/10.1007/s007050050187; PMID: 9672626
   PubMed Web of Science ®Google Scholar
• Rosenthal KL, Smiley JR, South S, Johnson DC. Cells expressing herpes simplex virus glycoprotein gC but not gB, gD, or gE are recognized by murine virus-specific cytotoxic T lymphocytes. J Virol 1987; 61:2438 - 47; PMID: 3037106
   PubMed Web of Science ®Google Scholar
• Eisenberg RJ, Ponce de Leon M, Cohen GH. Comparative structural analysis of glycoprotein gD of herpes simplex virus types 1 and 2. J Virol 1980; 35:428 - 35; PMID: 6255183
   PubMed Web of Science ®Google Scholar
• Dix RD, Pereira L, Baringer JR. Use of monoclonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease. Infect Immun 1981; 34:192 - 9; PMID: 6271681
   PubMed Web of Science ®Google Scholar
• Eing BR, Kühn JE, Braun RW. Neutralizing activity of antibodies against the major herpes simplex virus type 1 glycoproteins. J Med Virol 1989; 27:59 - 65; http://dx.doi.org/10.1002/jmv.1890270113; PMID: 2466100
   PubMed Web of Science ®Google Scholar
• Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007; 6:723 - 39; http://dx.doi.org/10.1586/14760584.6.5.723; PMID: 17931153
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G, Moreaux E, Desombre I, Crayne O, Francotte M, Pala P. Persistence of humoral and cellular immune response and booster effect following vaccination with herpes simplex (gD2t) candidate vaccine with MPL [abstract]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy 1994;205.
   Google Scholar
• Ahmad A, Sharif-Askari E, Fawaz L, Menezes J. Innate immune response of the human host to exposure with herpes simplex virus type 1: in vitro control of the virus infection by enhanced natural killer activity via interleukin-15 induction. J Virol 2000; 74:7196 - 203; http://dx.doi.org/10.1128/JVI.74.16.7196-7203.2000; PMID: 10906173
   PubMed Web of Science ®Google Scholar
• Khodai T, Chappell D, Christy C, Cockle P, Eyles J, Hammond D, et al. Single and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid A exhibit differential immunity that is not correlated to protection in animal models. Clin Vaccine Immunol 2011; 18:1702 - 9; http://dx.doi.org/10.1128/CVI.05071-11; PMID: 21852545
   PubMed Web of Science ®Google Scholar
• Hosken N, McGowan P, Meier A, Koelle DM, Sleath P, Wagener F, et al. Diversity of the CD8+ T-cell response to herpes simplex virus type 2 proteins among persons with genital herpes. J Virol 2006; 80:5509 - 15; http://dx.doi.org/10.1128/JVI.02659-05; PMID: 16699031
   PubMed Web of Science ®Google Scholar
• Morello CS, Levinson MS, Kraynyak KA, Spector DH. Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease. J Virol 2011; 85:3461 - 72; http://dx.doi.org/10.1128/JVI.02521-10; PMID: 21270160
   PubMed Web of Science ®Google Scholar
• Cattamanchi A, Posavad CM, Wald A, Baine Y, Moses J, Higgins TJ, et al. Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system. Clin Vaccine Immunol 2008; 15:1638 - 43; http://dx.doi.org/10.1128/CVI.00167-08; PMID: 18784341
   PubMed Web of Science ®Google Scholar
• Dervillez X, Gottimukkala C, Kabbara KW, Nguyen C, Badakhshan T, Kim SM, et al. Future of an “Asymptomatic” T-cell Epitope-Based Therapeutic Herpes Simplex Vaccine. Future Virol 2012; 7:371 - 8; http://dx.doi.org/10.2217/fvl.12.22; PMID: 22701511
   PubMed Web of Science ®Google Scholar
• Karpinski KF, Hayward S, Tryphonas H. Statistical considerations in the quantitation of serum immunoglobulin levels using the enzyme-linked immunosorbent assay (ELISA). J Immunol Methods 1987; 103:189 - 94; http://dx.doi.org/10.1016/0022-1759(87)90289-4; PMID: 3668258
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G, Van Hecke E, Michielsen W, Voet P, Hauser P, Pêtre J. Correlation between in vivo humoral and in vitro cellular immune responses following immunization with hepatitis B surface antigen (HBsAg) vaccines. Vaccine 1994; 12:812 - 8; http://dx.doi.org/10.1016/0264-410X(94)90290-9; PMID: 7975860
   PubMed Web of Science ®Google Scholar